Maryland-based Ventas, Inc. (VTR) is a healthcare real estate investment trust (REIT) that acquires, owns, and leases senior housing, life science, research & innovation (R&I), and healthcare properties. The company has a market cap of $45.2 billion and owns or operates approximately 1,450 properties in North America and the United Kingdom.
Companies with a market cap of $10 billion or more are typically called “large-cap stocks.” VTR fits squarely into that category, with a market cap above this threshold that reflects its substantial size and influence in the healthcare facilities REIT industry.
However, the stock currently trades 13.2% below its 52-week high of $101.60 recorded on July 28. VTR has grown 5.2% over the past three months, outperforming the State Street Real Estate Select Sector SPDR ETF’s (XLRE) 5.1% decline during the same time frame.
In the longer term, VTR has delivered a similar performance. The stock has grown 29.6% over the past 52 weeks, outpacing the 1.8% surge of XLRE over the same period. VTR has been trading above its 200-day moving average since last year and below its 50-day moving average since August.
On July 29, VTR announced the release of its better-than-expected Q2 2026 earnings. The company’s revenue for the quarter amounted to $1.7 billion and surpassed the Street’s forecasts. Additionally, its adjusted FFO for the period came in at $0.97, also topping the consensus estimates. Ventas expects full-year funds from operations in the range of $3.85 to $3.90 per share.
When stacked against its rival, Healthpeak Properties, Inc. (DOC) has grown 13.1% over the past year, lagging behind VTR.
Wall Street has a highly bullish view of the stock currently. Among the 23 analysts tracking VTR, the overall consensus stands at a “Strong Buy.” Its mean price target of $102 suggests a 15.7% upside potential from current price levels.
